Tumor Response on CT following hypofractionated stereotactic ablative body radiotherapy for small hypervascular hepatocellular carcinoma with cirrhosis

American Journal of Roentgenology

Volumn 201, Issue 6, 2013, Pages

  Sanuki, Naoko ^a   Takeda, Atsuya ^a   Mizuno, Tomikazu ^a   Oku, Yohei ^a   Eriguchi, Takahisa ^a   Iwabuchi, Shogo ^a   Kunieda, Etsuo ^b  

^a OFUNA CHUO HOSPITAL   (Japan)

^b TOKAI UNIVERSITY   (Japan)

Author keywords

Hepatocellular carcinoma; Modified response evaluation criteria in solid tumors; Stereotactic ablative body radiotherapy; Tumor marker

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; HYPERFRACTIONATED STEREOTACTIC ABLATIVE BODY RADIATION THERAPY; IATROGENIC DISEASE; IMAGE ANALYSIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; SMALL HYPERVASCULAR HEPATOCELLULAR CARCINOMA; STEREOTACTIC BODY RADIATION THERAPY; SURVIVAL RATE; THERAPY EFFECT; TREATMENT RESPONSE; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; RADIOSURGERY; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84888330280     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.12.10169     Document Type: Article

References (23)

1. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340:745-750.
2. Dawson LA, McGinn CJ, Normolle D, et al. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol 2000; 18: 2210-2218.
3. Tse RV, Hawkins M, Lockwood G, et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2008; 26:657-664.
4. Kang JK, Kim MS, Cho CK, et al. Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. Cancer 2012; 118:5424-5231.
5. Huang WY, Jen YM, Lee MS, et al. Stereotactic body radiation therapy in recurrent hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2012; 84:355-361.
6. Facciuto ME, Singh MK, Rochon C, et al. Stereotactic body radiation therapy in hepatocellular carcinoma and cirrhosis: evaluation of radiological and pathological response. J Surg Oncol 2012; 105:692-698.
7. Louis C, Dewas S, Mirabel X, et al. Stereotactic radiotherapy of hepatocellular carcinoma: preliminary results. Technol Cancer Res Treat 2010; 9:479-487.
8. Kwon JH, Bae SH, Kim JY, et al. Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection: stereotactic radiotherapy for liver cancer. BMC Cancer 2010; 10:475.
9. Andolino DL, Johnson CS, Maluccio M, et al. Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2011; 81:e447-e453.
10. Dewas S, Bibault JE, Mirabel X, et al. Prognostic factors affecting local control of hepatic tumors treated by stereotactic body radiation therapy. Radiat Oncol 2012; 7:166.
11. European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56:908-943.
12. Sanuki-Fujimoto N, Takeda A, Ohashi T, et al. CT evaluations of focal liver reactions following stereotactic body radiotherapy for small hepatocellular carcinoma with cirrhosis: relationship between imaging appearance and baseline liver function. Br J Radiol 2010; 83:1063-1071.
13. Takeda A, Oku Y, Sanuki N, et al. Dose volume histogram analysis of focal liver reaction in follow-up multiphasic CT following stereotactic body radiotherapy for small hepatocellular carcinoma. Radiother Oncol 2012; 104:374-378.
14. Herfarth KK, Hof H, Bahner ML, et al. Assessment of focal liver reaction by multiphasic CT after stereotactic single-dose radiotherapy of liver tumors. Int J Radiat Oncol Biol Phys 2003; 57:444-451.
15. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30:52-60.
16. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35:421-430.
17. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
18. Park W, Lim DH, Paik SW, et al. Local radiotherapy for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2005; 61:1143-1150.
19. Kim EY, Choi D, Lim do H, Lee WJ, Yoo BC, Paik SW. Change in contrast enhancement of HCC on 1-month follow-up CT after local radiotherapy: An early predictor of final treatment response. Eur J Radiol 2009; 72:440-446.
20. Katz AW, Chawla S, Qu Z, Kashyap R, Milano MT, Hezel AF. Stereotactic hypofractionated radiation therapy as a bridge to transplantation for hepatocellular carcinoma: clinical outcome and pathologic correlation. Int J Radiat Oncol Biol Phys 2012; 83:895-900.
21. Ibarra RA, Rojas D, Snyder L, et al. Multicenter results of stereotactic body radiotherapy (SBRT) for non-resectable primary liver tumors. Acta Oncol 2012; 51:575-583.
22. Price TR, Perkins SM, Sandrasegaran K, et al. Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma. Cancer 2012; 118:3191-3198.
23. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247.